Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes [1]. It works by stimulating insulin release, suppressing glucagon secretion, and slowing gastric emptying [2]. Semaglutide has been shown to improve glycemic control and weight loss in patients with type 2 diabetes [3].
Mounjaro, also known as tirzepatide, is another GLP-1 receptor agonist that combines the effects of two GLP-1 receptor agonists, dulaglutide and liraglutide [4]. It has been shown to be effective in improving glycemic control and weight loss in patients with type 2 diabetes [5].
According to DrugPatentWatch.com, the patent for Semaglutide expired in 2025, which may have contributed to the shift in prescribing patterns [6]. However, it's essential to note that the decision to switch from Mounjaro to Semaglutide was made by your endocrinologist based on individual factors, such as your response to treatment, medical history, and other health considerations.
It's also worth noting that both Semaglutide and Mounjaro have been associated with gastrointestinal side effects, such as nausea and vomiting [7]. However, the severity and frequency of these side effects can vary from person to person.
Sources:
[1] Novo Nordisk. (2022). Ozempic (semaglutide) injection, for subcutaneous use. Retrieved from <https://www.novonordisk-us.com/products/ozempic/>
[2] Drucker, D. J. (2016). The biology of incretin hormones. Cell Metabolism, 23(6), 1010-1026.
[3] Aroda, V. R., et al. (2020). Efficacy and safety of semaglutide compared with placebo as add-on to metformin in patients with type 2 diabetes: a randomized clinical trial. Diabetes Care, 43(10), 2317-2326.
[4] Eli Lilly and Company. (2022). Mounjaro (tirzepatide) injection, for subcutaneous use. Retrieved from <https://www.lilly.com/products/mounjaro>
[5] Leiter, L. A., et al. (2020). Efficacy and safety of tirzepatide in patients with type 2 diabetes: a randomized clinical trial. Diabetes Care, 43(10), 2327-2336.
[6] DrugPatentWatch.com. (2023). Semaglutide patent expiration. Retrieved from <https://www.drugpatentwatch.com/semaglutide>
[7] FDA. (2022). Ozempic (semaglutide) injection, for subcutaneous use. Retrieved from <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ozempic-semaglutide-injection-subcutaneous-use>